VISMEDERI SRL

Their core work

VisMederi is an Italian private laboratory specializing in serological testing and immunological assays for vaccine development, particularly for influenza and infectious diseases. Based in Siena — a historic hub for vaccine science — the company provides specialized analytical services such as hemagglutination inhibition (HI) assays, microneutralization tests, and immune response evaluation that support clinical trials and preclinical vaccine research. Their work spans from assessing vaccine efficacy and adjuvant performance to supporting next-generation delivery systems like microneedle patches and intradermal formulations.

What they specialise in

How they've shifted over time

VisMederi's early H2020 involvement (2016, PRONKJEWAIL) centered on broad infectious disease challenges — antimicrobial resistance, microbiome research, and personalized approaches to infection susceptibility. From 2020 onward, their focus sharpened considerably toward influenza vaccine development, novel delivery platforms (microneedle patches, intradermal formulations), and vaccine manufacturing innovation including AI-assisted modelling. The trajectory shows a clear move from general infection biology toward applied vaccine technology and industrialization.

VisMederi is moving toward applied vaccine delivery and manufacturing technologies, positioning itself as a testing partner for next-generation vaccine platforms beyond traditional injectable formulations.

How they like to work

VisMederi exclusively participates as a partner or third party — never as coordinator — which is typical of a specialized service provider contributing analytical expertise to larger consortia. With 78 unique partners across 17 countries in just 3 projects, they operate within large, multi-national research networks. This pattern suggests they are a trusted niche contributor that consortium leaders bring in for specific serological and immunological testing capabilities.

Despite only three projects, VisMederi has built a remarkably wide network of 78 partners across 17 countries, reflecting their role in large vaccine-focused consortia with broad European and international reach.

What sets them apart

VisMederi operates from Siena, historically one of Europe's most important vaccine development hubs (home to major vaccine producers). As a specialized SME focused on serological assays and vaccine immunogenicity testing, they fill a specific niche that large pharma and academic groups need but rarely maintain in-house at the same level of focus. Their combination of deep analytical expertise with involvement in next-generation delivery technologies (microneedles, intradermal patches) makes them a valuable bridge between vaccine R&D and clinical validation.

Highlights from their portfolio

• INDIGO
  Largest funding (EUR 777,720) focused on making flu vaccines affordable and accessible worldwide through needle-free delivery technologies like microneedle patches.
• Inno4Vac
  Long-running project (2021-2027) combining AI, in vitro models, and manufacturing innovation to accelerate vaccine development — signals VisMederi's forward-looking positioning.